Group 1 - The company, Jindan Technology (300829), stated that it will disclose relevant financial data for 2025 in future periodic reports and announcements [1] - The company emphasizes its commitment to comply with relevant laws and regulations, as well as the Information Disclosure Management Measures [1] - Currently, the company asserts that there is no significant information that should be disclosed but has not been [1]

Core Viewpoint - The inquiry response from Suzhou Lianxun Instrument Co., Ltd. reveals significant doubts regarding its technological independence, customer dependency, revenue authenticity, financial health, and information disclosure transparency as it approaches its listing on the Sci-Tech Innovation Board [2][15]. Group 1: Technological Independence - The company claims to possess core chips and self-developed algorithms, but a detailed examination shows a heavy reliance on outsourced components for its electronic measurement instruments and semiconductor testing equipment [3][4]. - The company admits that the development of specialized chips is costly and limited in market scope, leading to a reliance on third-party design and manufacturing services, raising questions about its technological barriers [5][17]. - The outsourcing of core chip development may undermine the company's competitive edge in a rapidly evolving market [18]. Group 2: Customer Dependency - The customer structure is heavily concentrated, with the top 10% of clients contributing approximately 75% of the company's revenue, indicating a high risk of revenue volatility if major clients alter their purchasing plans [5][6]. - The sales proportion to a key client has increased dramatically from 2.20% in 2022 to 12.53% in the first nine months of 2025, suggesting a deep dependency on a single customer [6][19]. - Despite efforts to diversify the customer base, the reliance on this major client remains significant, with projections indicating continued dependency [19]. Group 3: Revenue Recognition - The company exhibits a seasonal revenue pattern, with third and fourth quarters consistently outperforming the first and second quarters, raising concerns about potential revenue recognition manipulation [20]. - The explanation for this seasonal trend, attributed to client budget management, is met with skepticism, especially given the significant fluctuations in acceptance cycles across different years [20]. Group 4: Financial Health - The company faces increasing overdue accounts receivable, with amounts rising from approximately 27.22% to nearly 40% of total receivables by early 2025, indicating potential cash flow issues [21][22]. - Legal actions have been initiated against clients for unpaid debts, highlighting weaknesses in credit management and the collection of receivables [22]. Group 5: Information Disclosure - The company emphasizes its technological advancements but selectively omits competitive benchmarks, which may mislead investors regarding its market position [11][23]. - The lack of comprehensive comparisons with domestic competitors raises concerns about the transparency and objectivity of the company's claims regarding its technological capabilities [23].

证券日报网讯1月8日，博雅生物（300294）在互动平台回答投资者提问时表示，公司始终关注行业发展 趋势，并聚焦有利于提升公司核心竞争力、创造长期价值的战略机会。目前无应披露而未披露的信息， 请投资者以公司公告为准。 ...

Core Viewpoint - The company stated that any mergers and acquisitions will be treated as significant events and will comply with relevant laws and regulations regarding information disclosure [1] Group 1 - The company confirmed that it will strictly adhere to legal and regulatory requirements for information disclosure in the event of any merger or acquisition plans [1]

Group 1 - The company, Xingye Co., stated that it strictly adheres to the information disclosure obligations as per the regulations of the Shanghai Stock Exchange [2] - The company will disclose performance forecasts within the stipulated time if it meets the disclosure standards [2]

证券日报网讯1月5日，奥克股份（300082）在互动平台回答投资者提问时表示，海南奥克将利用自身优 势，结合相关政策，探索潜在机会，提升经营业绩。如有需披露信息，公司将严格按照法律法规履行信 息披露义务。 ...

证券日报网讯1月5日，海南发展（002163）在互动平台回答投资者提问时表示，若涉及应披露的事项， 公司将严格按照法律法规的规定及时履行信息披露义务。 ...

Core Viewpoint - Demar Technology (688360.SH) received an administrative regulatory measure decision from the Zhejiang Securities Regulatory Bureau, indicating violations related to the use of raised funds and inaccurate information disclosure [1][2][3]. Group 1: Regulatory Violations - From July 30 to August 5, 2020, Demar Technology used raised funds to pay unrelated land fees amounting to 5.8 million yuan [1]. - Between August 31, 2020, and September 27, 2023, the company used raised funds to cover expenses for a non-project "landscape restaurant" totaling 3.9451 million yuan [1]. - The company disclosed inaccuracies in its semi-annual and annual reports regarding the management and use of raised funds from March 2021 to August 2025 [1]. Group 2: Accountability of Company Personnel - The chairman and general manager, Zhuo Xu, the then financial officer, Chen Xueqiang, the then board secretary, Guo Aihua, and the current financial director and board secretary, Huang Hai, failed to ensure proper use of raised funds and fulfill information disclosure obligations [2]. - The actions of these individuals violated multiple regulations outlined in the Securities Regulatory Guidelines and Information Disclosure Management Measures [2]. Group 3: Regulatory Measures and Company Response - The Zhejiang Securities Regulatory Bureau decided to issue warning letters to the company and the aforementioned individuals, which will be recorded in the securities market integrity archives [3]. - Demar Technology expressed its commitment to addressing the issues raised in the decision and will submit a written rectification report to the Zhejiang Securities Regulatory Bureau within the specified timeframe [3]. - The company aims to enhance its compliance with securities laws and improve the quality of information disclosure to protect the interests of shareholders and promote stable, high-quality development [3]. Group 4: Company Financial Information - Demar Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 2, 2020, issuing 21,419,150 shares at a price of 25.12 yuan per share [4]. - The total amount raised from the initial public offering was 538.049 million yuan, with a net amount of 460.9362 million yuan, exceeding the original fundraising target by 82.9551 million yuan [4]. - The total issuance costs for the IPO were 77.1128 million yuan, with Everbright Securities receiving 55.5799 million yuan in underwriting and sponsorship fees [4].

Core Insights - In 2025, Guangdong Tianenkang Pharmaceutical Co., Ltd. (referred to as "Tianenkang") is committed to the core philosophy of "putting investors first," focusing on information disclosure, corporate governance, market value management, and social responsibility to enhance compliance and steadily increase corporate value [1][2] Group 1: Corporate Achievements - Tianenkang has received multiple authoritative awards for its outstanding performance in innovation research and development, market value management, corporate governance, and ESG practices, reflecting broad market recognition of its high-quality development [1] - On December 15, 2025, Tianenkang was included in the sample range of the CSI 1000 Index, indicating robust fundamental operations and good market liquidity, which marks its investment value recognized by index compilers [1] - The company launched an employee stock ownership plan on August 5, 2025, to stimulate internal motivation and inject strong momentum for long-term development [1] Group 2: Investor Relations Management - Tianenkang has established multiple communication channels for investor relations, holding two performance briefings and receiving over 200 institutional visits throughout the year, including six research meetings with various institutions [2] - The company responded to 51 investor inquiries on the interactive platform, focusing on key investor concerns such as CKBA clinical progress and product development pipeline [2] - In 2025, Tianenkang laid a solid foundation for high-quality development through precise information disclosure, an efficient governance system, innovative market value management, and solid ESG practices, with plans to deepen investor communication and optimize capital operation strategies [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has released a draft for the "Regulations on the Supervision of Company Secretaries of Listed Companies," aiming to clarify the responsibilities of company secretaries, enhance their performance, and ensure compliance in corporate governance [1]. Group 1: Responsibilities of Company Secretaries - The regulations further detail the scope of responsibilities for company secretaries [2]. - Company secretaries are positioned as "supervisors" of compliance in corporate governance [3]. - They are tasked with organizing and overseeing information disclosure activities, ensuring compliance with corporate governance, and facilitating effective internal and external communication [9][10]. Group 2: Support Mechanisms for Performance - The regulations establish mechanisms for information acquisition, performance platforms, and remedies to support company secretaries in fulfilling their duties [12]. - A comprehensive information acquisition mechanism is mandated, allowing company secretaries to access necessary information and participate in key meetings [13]. - Diverse performance platforms are required, including dedicated support from the company and enhanced communication among supervisory bodies [13]. Group 3: Professional Qualifications and Management - Companies must ensure that appointed company secretaries possess the necessary professional qualifications to fulfill their roles [14]. - The nomination committee is responsible for reviewing the qualifications of company secretaries [6]. - Company secretaries are prohibited from holding positions that may lead to conflicts of interest, ensuring they have adequate time to perform their duties [14]. Group 4: Accountability and Enforcement - The regulations emphasize the establishment of a regular evaluation and accountability mechanism for company secretaries [7]. - Internal and external accountability measures are reinforced, with companies required to initiate internal accountability procedures for underperformance [15]. - Strict regulatory measures will be applied to company secretaries who fail to fulfill their responsibilities, particularly in cases of non-compliance with information disclosure requirements [15].